Please wait while the formulary information is being retrieved.
XYLOCAINE IV (LIDOCAINE HCL/PF)
- Ventricular arrhythmias
Xylocaine (Cardiac) (PF) 20 mg/mL (2 %) intravenous solution
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- Acid Reducer (cimetidine)
- Acid Relief (cimetidine)
- Anectine
- Bystolic
- cimetidine
- Corgard
- Corzide
- Dutoprol
- Heartburn Relief
- Inderal La
- Inderal Xl
- Innopran Xl
- Lopressor
- Lopressor Hct
- metoprolol su-hydrochlorothiaz
- metoprolol succinate
- metoprolol ta-hydrochlorothiaz
- metoprolol tartrate
- nadolol
- nadolol-bendroflumethiazide
- nebivolol
- propranolol
- propranolol-hydrochlorothiazid
- Quelicin
- succinylcholine chloride
- Tagamet Hb
- Toprol Xl
- Adams-stokes syndrome
- Methemoglobinemia
- Severe heart block
- Systemic lidocaine toxicity
- Wolff-parkinson-white pattern
Contraindicated
- Chronic heart failure
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Hemolytic anemia from PK and g6PD deficiencies
- Hypokalemia
- Hypovolemia
- Hypoxia
- Incomplete AV heart block
- Myasthenia gravis
- Respiratory depression
- Shock
- Sinus bradycardia
Severe
Moderate
- Atrial fibrillation
- Disease of liver
XYLOCAINE IV (LIDOCAINE HCL/PF)
- Ventricular arrhythmias
- None
- None
More Frequent
Severe
Less Severe
- Bradycardia
- Hypotension
- Dizziness
- Drowsy
- Injection site sequelae
- Nervousness
- Paresthesia
- Sensation of cold
- Symptoms of anxiety
- Twitching
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Cardiac arrest
- Diplopia
- Dyspnea
- Methemoglobinemia
- Nausea
- Respiratory depression
- Seizure disorder
- Unconsciousness
Less Severe
- Apprehension
- Euphoria
- Oral hypoesthesia
- Tinnitus
- Tremor
- Vomiting
Contraindicated
None
Severe Precaution
Lidocaine (Select routes)
Rare risk of methemoglobinemia in infants age < 6 months. Risk of systemic toxicity. Monitor for CNS toxicity (e.g. restlessness, dizziness, drowsiness, blurred vision) with prolonged infusion, repeated injections or application. Limited safety data available.
- 1 Day – 179 Days
- Rare risk of methemoglobinemia in infants age < 6 months. Risk of systemic toxicity. Monitor for CNS toxicity (e.g. restlessness, dizziness, drowsiness, blurred vision) with prolonged infusion, repeated injections or application. Limited safety data available.
- 180 Days – 16 Years
- Rare risk of methemoglobinemia in infants age < 6 months. Risk of systemic toxicity. Monitor for CNS toxicity (e.g. restlessness, dizziness, drowsiness, blurred vision) with prolonged infusion, repeated injections or application. Limited safety data available.
Management or Monitoring Precaution
None
Lidocaine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Lidocaine
Amount excreted reported to be low with low infant oral bioavailability
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | Not known; no or inclusive data | Amount excreted reported to be low with low infant oral bioavailability |
Contraindicated
None
Precaution Exists
Select Anesthetics
General-May be more sensitive to CNS and cardiac adverse reactions. Consider dose reduction due to reduced clearance in the elderly.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Ventricular arrhythmias | |
| I49.01 | Ventricular fibrillation |
| I49.02 | Ventricular flutter |
| I49.9 | Cardiac arrhythmia, unspecified |
| 0-9 | A-Z |
|---|---|
| I49.01 | Ventricular fibrillation |
| I49.02 | Ventricular flutter |
| I49.9 | Cardiac arrhythmia, unspecified |
Formulary Reference Tool